JP5572863B2 - Ｎｋ細胞の増幅方法 - Google Patents

Ｎｋ細胞の増幅方法 Download PDF

Info

Publication number
JP5572863B2
JP5572863B2 JP2012021972A JP2012021972A JP5572863B2 JP 5572863 B2 JP5572863 B2 JP 5572863B2 JP 2012021972 A JP2012021972 A JP 2012021972A JP 2012021972 A JP2012021972 A JP 2012021972A JP 5572863 B2 JP5572863 B2 JP 5572863B2
Authority
JP
Japan
Prior art keywords
cells
cell
positive
amplification
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012021972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013027385A (ja
JP2013027385A5 (enExample
Inventor
吉和 米満
結 原田
智 齊藤
雄一郎 矢崎
正人 岡本
武文 石田尾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyushu University NUC
Tella Inc
Original Assignee
Kyushu University NUC
Tella Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2012021972A priority Critical patent/JP5572863B2/ja
Application filed by Kyushu University NUC, Tella Inc filed Critical Kyushu University NUC
Priority to MYPI2013004630A priority patent/MY161389A/en
Priority to CN201280031188.5A priority patent/CN103620022B/zh
Priority to US14/129,143 priority patent/US9404083B2/en
Priority to AU2012274478A priority patent/AU2012274478B2/en
Priority to KR1020147001579A priority patent/KR101963920B1/ko
Priority to HK14103574.2A priority patent/HK1190432B/xx
Priority to CA2840161A priority patent/CA2840161C/en
Priority to PCT/JP2012/065718 priority patent/WO2012176796A1/ja
Priority to EP12801859.5A priority patent/EP2725100B1/en
Publication of JP2013027385A publication Critical patent/JP2013027385A/ja
Publication of JP2013027385A5 publication Critical patent/JP2013027385A5/ja
Application granted granted Critical
Publication of JP5572863B2 publication Critical patent/JP5572863B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012021972A 2011-06-24 2012-02-03 Ｎｋ細胞の増幅方法 Active JP5572863B2 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2012021972A JP5572863B2 (ja) 2011-06-24 2012-02-03 Ｎｋ細胞の増幅方法
PCT/JP2012/065718 WO2012176796A1 (ja) 2011-06-24 2012-06-20 Ｎｋ細胞の増幅方法
US14/129,143 US9404083B2 (en) 2011-06-24 2012-06-20 Method for amplifying NK cells
AU2012274478A AU2012274478B2 (en) 2011-06-24 2012-06-20 Method for amplifying NK cells
KR1020147001579A KR101963920B1 (ko) 2011-06-24 2012-06-20 Nk 세포의 증폭 방법
HK14103574.2A HK1190432B (en) 2011-06-24 2012-06-20 Method for amplifying nk cells
MYPI2013004630A MY161389A (en) 2011-06-24 2012-06-20 Method for amplifying nk cells
CN201280031188.5A CN103620022B (zh) 2011-06-24 2012-06-20 Nk细胞的扩增方法
EP12801859.5A EP2725100B1 (en) 2011-06-24 2012-06-20 Method for amplifying nk cells
CA2840161A CA2840161C (en) 2011-06-24 2012-06-20 Method for amplifying nk cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011140725 2011-06-24
JP2011140725 2011-06-24
JP2012021972A JP5572863B2 (ja) 2011-06-24 2012-02-03 Ｎｋ細胞の増幅方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014011951A Division JP5989016B2 (ja) 2011-06-24 2014-01-27 Ｎｋ細胞の増幅方法

Publications (3)

Publication Number Publication Date
JP2013027385A JP2013027385A (ja) 2013-02-07
JP2013027385A5 JP2013027385A5 (enExample) 2013-12-12
JP5572863B2 true JP5572863B2 (ja) 2014-08-20

Family

ID=47422628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012021972A Active JP5572863B2 (ja) 2011-06-24 2012-02-03 Ｎｋ細胞の増幅方法

Country Status (9)

Country Link
US (1) US9404083B2 (enExample)
EP (1) EP2725100B1 (enExample)
JP (1) JP5572863B2 (enExample)
KR (1) KR101963920B1 (enExample)
CN (1) CN103620022B (enExample)
AU (1) AU2012274478B2 (enExample)
CA (1) CA2840161C (enExample)
MY (1) MY161389A (enExample)
WO (1) WO2012176796A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018207900A1 (ja) 2017-05-12 2018-11-15 米満　吉和 高活性ｎｋ細胞、およびその利用
WO2019189115A1 (ja) 2018-03-27 2019-10-03 株式会社ガイアバイオメディシン ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用並びにその製造方法
WO2020152661A1 (ja) 2019-01-21 2020-07-30 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5511039B1 (ja) * 2013-05-22 2014-06-04 国立大学法人九州大学 Ｎｋ細胞の調製方法
JP6164650B2 (ja) * 2014-01-20 2017-07-19 国立大学法人九州大学 Ｎｋ細胞の調製方法
WO2015132415A1 (en) * 2014-03-07 2015-09-11 Emercell Sas Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
US12398371B2 (en) 2015-01-27 2025-08-26 Korea Research Institute Of Bioscience Method for mass producing natural killer cell and use of natural killer cell obtained by the method as anti-cancer agent
WO2016122014A1 (ko) * 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
CN106222141B (zh) * 2016-10-17 2018-10-19 湖南丰晖生物科技有限公司 Nk细胞培养液和细胞培养方法
CN110662834B (zh) 2017-05-26 2023-09-12 Gc细胞治疗 使用转化的t细胞培养自然杀伤细胞的方法
KR102765799B1 (ko) * 2018-02-01 2025-02-13 주식회사 엔케이맥스 Cd56+ 자연살해세포를 포함하는 항암용 조성물
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
WO2019152663A1 (en) * 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN110628714B (zh) * 2018-06-21 2023-03-28 精准生技股份有限公司 用于体外扩增自然杀手细胞及自然杀手t细胞的无血清细胞培养液
CN109161527A (zh) * 2018-09-25 2019-01-08 深圳市五零生命科技有限公司 一种高效的nk细胞扩增方法
EP3892721A4 (en) * 2018-11-14 2022-08-31 GC Cell Corporation METHOD FOR CULTIVATING NATURAL KILLER CELLS DERIVED FROM UMBILICAL CORD BLOOD USING TRANSFORMED T LYMPHOCYTES
JP6838750B2 (ja) 2019-01-21 2021-03-03 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
KR102234394B1 (ko) * 2019-03-08 2021-03-31 신지섭 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제
KR102216710B1 (ko) * 2019-03-27 2021-02-17 신지섭 Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물
JP6697611B2 (ja) * 2019-05-20 2020-05-20 米満　吉和 高活性ｎｋ細胞、およびその利用
CN111154721B (zh) * 2020-01-14 2023-10-17 深圳格泰赛尔生物科技有限公司 Nk细胞扩增方法
US20230040477A1 (en) * 2020-01-19 2023-02-09 Board Of Regents, The University Of Texas System T-cell death associated gene 8 (tdag8) modulation to enhance cellular cancer therapies
US12486492B2 (en) 2020-03-05 2025-12-02 Korea Research Institute Of Bioscience Method for producing memory-like NK cells with ability to express higher levels of NCRs, cytotoxicity, and IFN-γ than NK cells in human peripheral blood
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2023081813A1 (en) 2021-11-05 2023-05-11 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors
EP4536687A1 (en) 2022-06-08 2025-04-16 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy
WO2025022372A1 (ja) * 2023-07-21 2025-01-30 株式会社ガイアバイオメディシン 細胞集団の製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068306A1 (en) * 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
US7544355B2 (en) * 2002-03-13 2009-06-09 Universita Degli Studi Di Perugia Methods and compositions for allogeneic transplantation
AU2003294930B2 (en) 2002-12-23 2008-12-04 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2006050270A2 (en) * 2004-11-02 2006-05-11 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
CA2645042A1 (en) 2006-03-06 2007-09-13 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
JP2007297292A (ja) 2006-04-28 2007-11-15 Kyorin Pharmaceut Co Ltd １−アルコキシイソキノリン誘導体又はその水和物の製造方法
JP4275680B2 (ja) 2006-04-28 2009-06-10 裕 照沼 リンパ球の活性・増殖に係る培養方法
WO2008023874A1 (en) * 2006-08-23 2008-02-28 Binex Co., Ltd. Manufacturing method of activated lymphocytes for immunotherapy
JP4861420B2 (ja) 2006-08-28 2012-01-25 久光製薬株式会社 爪用貼付剤
JP2010220479A (ja) * 2007-06-15 2010-10-07 Medeinetto:Kk Ｎｋ細胞の培養方法及びｎｋ細胞の利用
AU2008307633C1 (en) * 2007-09-28 2015-04-30 Celularity Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
DK2279253T3 (en) * 2008-04-09 2017-02-13 Maxcyte Inc Construction and application of therapeutic compositions of freshly isolated cells
KR101133185B1 (ko) * 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
JP2012521215A (ja) * 2009-03-26 2012-09-13 アヴァリス・アクチエボラーグ Ｎｋ細胞の増殖
CN102597223B (zh) * 2009-09-11 2017-05-10 宝生物工程株式会社 生产天然杀伤细胞的方法
EP2519239B1 (en) 2009-12-29 2017-03-08 Gamida Cell Ltd. Methods for enhancing natural killer cell proliferation and activity
JP2011239701A (ja) 2010-05-14 2011-12-01 Tella Inc 樹状細胞の培養方法
KR101039843B1 (ko) 2010-08-30 2011-06-09 주식회사 엔케이바이오 자기활성화 림프구 배양용 배지 조성물 및 이를 이용한 자기활성화 림프구 배양방법
JP5840876B2 (ja) 2011-06-24 2016-01-06 テラ株式会社 Ｎｋ細胞を増幅するための組成物及び方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018207900A1 (ja) 2017-05-12 2018-11-15 米満　吉和 高活性ｎｋ細胞、およびその利用
US11723924B2 (en) 2017-05-12 2023-08-15 Yoshikazu Yonemitsu Highly active NK cell and use thereof
US12329817B2 (en) 2017-05-12 2025-06-17 Yoshikazu Yonemitsu Highly active NK cell and use thereof
WO2019189115A1 (ja) 2018-03-27 2019-10-03 株式会社ガイアバイオメディシン ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用並びにその製造方法
US11987812B2 (en) 2018-03-27 2024-05-21 Gaia Biomedicine Inc. Population of CD3-negative cells that express chemokine receptor and cell adhesion molecule, use of the same, and method for producing the same
WO2020152661A1 (ja) 2019-01-21 2020-07-30 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法

Also Published As

Publication number Publication date
JP2013027385A (ja) 2013-02-07
EP2725100A4 (en) 2015-01-07
US20140120072A1 (en) 2014-05-01
MY161389A (en) 2017-04-14
EP2725100A1 (en) 2014-04-30
US9404083B2 (en) 2016-08-02
EP2725100B1 (en) 2019-09-04
AU2012274478A1 (en) 2014-02-20
CN103620022B (zh) 2015-09-30
KR20140051263A (ko) 2014-04-30
CN103620022A (zh) 2014-03-05
CA2840161A1 (en) 2012-12-27
KR101963920B1 (ko) 2019-03-29
AU2012274478B2 (en) 2017-03-30
AU2012274478A8 (en) 2016-07-28
WO2012176796A1 (ja) 2012-12-27
HK1190432A1 (en) 2014-07-04
CA2840161C (en) 2019-02-12

Similar Documents

Publication Publication Date Title
JP5572863B2 (ja) Ｎｋ細胞の増幅方法
JP5511039B1 (ja) Ｎｋ細胞の調製方法
US11723924B2 (en) Highly active NK cell and use thereof
KR102534472B1 (ko) 케모카인 리셉터와 세포 접착 분자를 발현하는 cd3 음성 세포의 집단, 및 그 이용 그리고 그 제조 방법
JP5989016B2 (ja) Ｎｋ細胞の増幅方法
TWI757709B (zh) 含有nk細胞之細胞集團之製造方法
JP6164650B2 (ja) Ｎｋ細胞の調製方法
JP6697611B2 (ja) 高活性ｎｋ細胞、およびその利用
JP2020108405A (ja) 高活性ｎｋ細胞、およびその利用
JP2011239701A (ja) 樹状細胞の培養方法
HK1190432B (en) Method for amplifying nk cells
JP2023153286A (ja) Ｎｋ細胞を含む細胞集団の製造方法
JP6426767B2 (ja) 樹状細胞の培養方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121024

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131025

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20131025

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20131112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140527

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140612

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140611

R150 Certificate of patent or registration of utility model

Ref document number: 5572863

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250